Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDFIC 2 long-term open-label extension of A4250 in children with PFIC types 1 and 2
2017-002325-38Phase 3Completed
- Sponsor
- Albireo Pharma
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis type 1 (PFIC1), progressive familial intrahepatic cholestasis type 2 (PFIC2) and progressive familial intrahepatic cholestasis (PFIC), sponsored by Albireo Pharma. Started Jun 2018; status: completed.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis type 1 (PFIC1)progressive familial intrahepatic cholestasis type 2 (PFIC2)progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on 2017-002325-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002325-38.